Circulatory microRNA expression profile for coronary artery calcification in chronic kidney disease patients

Abstract

Background & Aim: Coronary artery disease (CAD) is the primary cause of mortality in patients with end stage renal disease (ESRD). MicroRNA profiling is proven as a powerful tool in the diagnosis of any disease at the molecular level. Hence, the present study aimed to profile the microRNA expression for CAD especially coronary artery calcification in CKD patients.
 Materials and Methods: Two hundread patients with CKD stages 3 to 5 without dialysis and healthy controls were includ- ed in this study. All two hundred patients underwent 1024 multi sliceardiac computed tomography (CT) scan for calcium scoring. The calcium scoring more than 100 have been included in the study. We performed miRNA microarray analysis from serum samples of seven high calcium scored with CKD patients and one control patients.
 Results: Seven patients have observed circulating miRNAs has significantly upregulated and downregulated when compared with control patients. mir21, mir 67, mir 390, mir 56, mir 250, mir 65 and mir 13 were up regulated and mir235, mir256, mir226, mir207, mir255, mir193 were downregulated. There was no significant difference in left ventricle function.
 Conclusion: 13 microRNAs play a potential role in coronary artery calcification in CKD patients.
 Keywords: CKD; CAD; microRNA; coronary artery calcification.

Analysis of miRNA Associated with Coronary Artery Calcification

“…Calcification of atherosclerotic plaques is secondary to the development of coronary artery disease. Early detection of coronary calcification is an important marker for early diagnosis [19][20][21][22][23][24]. MicroRNA is a factor related to the formation of atherosclerosis that has been concerned in recent years.…”

Micro-RNA-93-5p and micro-RNA-3613-5p in exosomes released from vascular endothelial cells regulate medial arterial calcification in hemodialysis patients

“…Chao et al [25] discovered that serum miR-125b2-3p and miR-378a-3p levels decreased with increasing severity of VC in 155 CKD patients. Another study demonstrated that the serum levels of 13 miRNAs (up-regulated: miR-21, miR-67, miR-390, miR-56, miR-250, miR-65, miR-13; down-regulated: miR-235, miR-256, miR-226, miR-207, miR255, miR193) differed signi cantly in seven CKD patients compared with control patients [26]. Because of the complex situations in patients, the characteristics of circulating miRNAs and exosome cargo miRNAs may differ.…”

Flow-Responsive Noncoding RNAs in the Vascular System: Basic Mechanisms for the Clinician

“…LncRNA are able to exert an array of biological func tions, including: (1) regulation of DNA transcription by acting with a transcription facto (2) epigenetic silencing and repressing the histone modification via chromatin interaction (3) mRNA translation (4) post-translational regulation through miRNA sponges o circRNA, (5) scaffold of protein complex, (6) shorter ncRNAs (siRNA) generation (Figur 1B). Noncoding RNAs are largely involved in cardiovascular physiology, atherosclerosi [35], and multiple cardiovascular diseases [36], as chronic and acute coronary syndrome [6,[37][38][39][40][41], vascular remodeling [29,42], valvular heart disease [43][44][45][46][47], generation and pro gression of ectopic calcifications in the cardiovascular system [48][49][50][51][52][53][54], platelet functio [55][56][57][58][59], heart failure and stroke [60][61][62][63][64][65][66][67][68][69][70]. Evidence of the impact of flow conditions on cir culating ncRNA derives both from observations on pathological changes, such as cardia valve disease, vascular stenoses or aneurysm, but also from physiological conditions, suc as exercise [68].…”

“…This review focuses on regulatory noncoding RNAs that are directly or indirectl responsive to flow and their involvement with cardiovascular effects of altered bloo flow, with a focus on the potential clinical relevance and the underlying molecular mech anisms and their possible use as clinical biomarkers [71]. As relevant evidence is no equally available for all ncRNAs sub-categories, some specific ncRNAs, including siR NAs, snoRNA or piRNA are not mentioned in this review due to lack of evidence in rela Noncoding RNAs are largely involved in cardiovascular physiology, atherosclerosis [35], and multiple cardiovascular diseases [36], as chronic and acute coronary syndromes [6,[37][38][39][40][41], vascular remodeling [29,42], valvular heart disease [43][44][45][46][47], generation and progression of ectopic calcifications in the cardiovascular system [48][49][50][51][52][53][54], platelet function [55][56][57][58][59], heart failure and stroke [60][61][62][63][64][65][66][67][68][69][70]. Evidence of the impact of flow conditions on circulating ncRNA derives both from observations on pathological changes, such as cardiac valve disease, vascular stenoses or aneurysm, but also from physiological conditions, such as exercise…”